«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2021年04期

页码:

533-535

栏目:

综述

出版日期:

2021-08-20

文章信息/Info

Title:

-

作者:

张 倩¹; 高永恒¹; 郑开福²; 金发光¹

710038 西安,空军(第四)军医大学唐都医院呼吸与危重症医学科¹、胸外科²

Author(s):

-

关键词:

新辅助治疗;  免疫疗法;  非小细胞肺癌

Keywords:

-

分类号:

R734.2

DOI:

10.3877/cma.j.issn.1674-6902.2021.04.038

摘要:

-

Abstract:

-

参考文献/References:

1 钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2 Bade BC, Dela CC. Lung Cancer 2020: Epidemiology, Etiology, and Prevention[J]. Clin Chest Med, 2020, 41(1): 1-24.
3 Board PATE. Non-Small Cell Lung Cancer Treatment(PDQ?): Health Professional Version[M]. 2002.
4 Siddiqui F, Siddiqui AH. Cancer, Lung[M]. 2020.
5 Bunn PJ, Schenk E, Pacheco J, et al. New developments in neoadjuvant therapy for lung cancer[J]. Oncology(Williston Park), 2019, 33(3): 101-106, 109.
6 Group NCLC. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials[J]. BMJ, 1995, 311(7010): 899-909.
7 Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage ⅠB-ⅢA non-small-cell lung cancer(Adjuvant Navelbine International Trialist Association[ANITA]): a randomised controlled trial[J]. Lancet Oncol, 2006, 7(9): 719-727.
8 Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group[J]. J Clin Oncol, 2008, 26(21): 3552-3559.
9 Urushiyama H, Jo T, Yasunaga H, et al. Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage Ⅱ-ⅢA non-small cell lung cancer: Propensity score-matched and instrumental variable analyses [J]. Cancer Med, 2018, 7(10): 4863-4869.
10 Group NMC. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data[J]. Lancet, 2014, 383(9928): 1561-1571.
11 Marur S, Singh H, Mishra-Kalyani P, et al. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies [J]. Semin Oncol, 2018, 45(4): 220-225.
12 Barlesi F, Vansteenkiste J, Spigel D, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer(JAVELIN Lung 200): an open-label, randomised, phase 3 study[J]. Lancet Oncol, 2018, 19(11): 1468-1479.
13 Reck M, Mok T, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer(IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial[J]. Lancet Respir Med, 2019, 7(5): 387-401.
14 de Silva M, Itchins M, Pavlakis N. Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition[J]. Ann Transl Med, 2020, 8(8): 555.
15 Vansteenkiste JF, Cho BC, Vanakesa T, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer(MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2016, 17(6): 822-835.
16 Owen D, Chaft JE. Immunotherapy in surgically resectable non-small cell lung cancer[J]. J Thorac Dis, 2018, 10(Suppl 3): S404-S411.
17 Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non small-cell lung cancer treated with pembrolizumab: Results from the Phase I KEYNOTE-001 study [J]. J Clin Oncol, 2019, 37(28): 2518-2527.
18 Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer [J]. N Engl J Med, 2018, 378(22): 2078-2092.
19 Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639.
20 Ikeda S, Kato T, Kenmotsu H, et al. A phase Ⅱ study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study[J]. Ther Adv Med Oncol, 2020, 12: 431430234.
21 Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J]. N Engl J Med, 2018, 378(24): 2288-2301.
22 Lavin Y, Kobayashi S, Leader A, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses[J]. Cell, 2017, 169(4): 750-765.
23 Rhodin KE, Rucker AJ, Ready NE, et al. The immunotherapeutic landscape in non-small cell lung cancer and its surgical horizons[J]. J Thorac Cardiovasc Surg, 2020, 159(4): 1616-1623.
24 El KM, Rajan A. Neoadjuvant immunotherapy for non-small cell lung cancer: can early intervention result in durable clinical benefit?[J]. J Thorac Dis, 2018, 10(Suppl 26): S3203-S3206.
25 Ghysen K, Vansteenkiste J. Immunotherapy in patients with early stage resectable nonsmall cell lung cancer[J]. Curr Opin Oncol, 2019, 31(1): 13-17.
26 Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer[J]. N Engl J Med, 2018, 378(21): 1976-1986.
27 Bar J, Urban D, Ofek E, et al. Neoadjuvant pembrolizumab(Pembro) for early stage non-small cell lung cancer(NSCLC): Updated report of a phase I study, MK3475-223[J]. JCO, 2019, 37: 8534.
28 Kwiatkowski D, Rusch V, Chaft J, et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer(NSCLC): Interim analysis and biomarker data from a multicenter study(LCMC3)[J]. JCO, 2019, 37(suppl): abstr 8503.
29 Gao S, Li N, Gao S, et al. Neoadjuvant PD-1 inhibitor(Sintilimab)in NSCLC[J]. J Thorac Oncol, 2020, 15(5): 816-826.
30 Hellmann MD, Chaft JE, William W J, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint[J]. Lancet Oncol, 2014, 15(1): e42-e50.
31 Cascone T, William W, Weissferdt A, et al. Neoadjuvant nivolumab(N)or nivolumab plus ipilimumab(NI)for resectable non-small cell lung cancer(NSCLC): Clinical and correlative results from the NEOSTAR study[J]. JCO, 2019, 37(suppl): abstr 8504.
32 Provencio M, Nadal E, Insa A, et al. NADIM Study: Updated clinical research and outcomes[J]. J Thorac, 2019, 14: S241.
33 Shu CA, Gainor JF, Awad MM, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(6): 786-795.
34 Kilickap S, Demirci U, Karadurmus N, et al. Endpoints in oncology clinical trials[J]. J BUON, 2018, 23(7): 1-6.

备注/Memo

备注/Memo:

基金项目: 国家自然科学基金面上项目(81970076)
通信作者: 金发光, Email: jinfag@fmmu.edu.cn

常用功能

更新日期/Last Update: 2021-08-20